NCT00875446View on ClinicalTrials.gov

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 13, 2009

Primary Completion Date

September 9, 2011

Study Completion Date

September 9, 2011

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

PLACEBO

Placebo

DRUG

GSK1223249

I.V Infusion

Trial Locations (12)

13210

GSK Investigational Site, Syracuse

21287

GSK Investigational Site, Baltimore

27157

GSK Investigational Site, Winston-Salem

37134

GSK Investigational Site, Verona

75013

GSK Investigational Site, Paris

NY 10021

GSK Investigational Site, New York

NC 28207-1885

GSK Investigational Site, Charlotte

OH 43210

GSK Investigational Site, Columbus

B15 2TH

GSK Investigational Site, Birmingham

CB2 2GG

GSK Investigational Site, Cambridge

NW3 2PF

GSK Investigational Site, London

SE5 8AF

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY